Matthew L. Sherman

Randomized Phase II Study of Multiple Dose Levels of CCI-779, a Novel Mammalian Target of Rapamycin Kinase Inhibitor, in Patients With Advanced Refractory Renal Cell Carcinoma

Michael B. Atkins, Manuel Hidalgo, Walter M. Stadler et al. · Journal of Clinical Oncology · 2004 · 943 citations · Full text

Pharmacy, Oncology, Pharmacology +16

Efficacy and Safety of Gemtuzumab Ozogamicin in Patients With CD33-Positive Acute Myeloid Leukemia in First Relapse

Eric L. Sievers, Richard A. Larson, Edward A. Stadtmauer et al. · Journal of Clinical Oncology · 2001 · 893 citations

Medicine, Hematology, Pharmacology +17

Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production.

John P. Leonard, Matthew L. Sherman, Gerald L. Fisher et al. · PubMed · 1997 · 814 citations

Pharmacy, Immunology, Toxicology +16

Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies.

Michael B. Atkins, Michael J. Robertson, Michael S. Gordon et al. · PubMed · 1997 · 590 citations

Medicine, Oncology, Pharmacology +15

Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes

Pierre Fenaux, Uwe Platzbecker, Ghulam J. Mufti et al. · New England Journal of Medicine · 2020 · 537 citations · Full text

Medicine, Hematology, Pharmacotherapy +16